Eosinophil Proportion May Serve as a Candidate Biomarker for Adverse Events in Patients With Urothelial Carcinoma Treated With Enfortumab Vedotin - Kunihiro Odagiri; Toshiharu Morikawa; Taku Naiki; Yosuke Sugiyama; Yoshihiko Tasaki; Yoshihisa Mimura; Aya Naiki‐Ito; Takashi Nagai; Toshiki Etani; Keitaro Iida; Daiki Ishikawa; Yusuke Noda; et al. (Cancer Medicine, 2026)